0001062993-24-008821.txt : 20240426 0001062993-24-008821.hdr.sgml : 20240426 20240426081057 ACCESSION NUMBER: 0001062993-24-008821 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240418 FILED AS OF DATE: 20240426 DATE AS OF CHANGE: 20240426 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cardiol Therapeutics Inc. CENTRAL INDEX KEY: 0001702123 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40712 FILM NUMBER: 24878912 BUSINESS ADDRESS: STREET 1: 602-2265 UPPER MIDDLE ROAD EAST CITY: OAKVILLE STATE: A6 ZIP: L6H 0G5 BUSINESS PHONE: 289-910-0850 MAIL ADDRESS: STREET 1: 602-2265 UPPER MIDDLE ROAD EAST CITY: OAKVILLE STATE: A6 ZIP: L6H 0G5 6-K 1 form6k.htm FORM 6-K Cardiol Therapeutics Inc.: Form 6-K - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2024

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[X] Form 20-F     [   ] Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [   ]

SUBMITTED HEREWITH

Exhibits

Exhibit   Description
   
99.1   Notice of Meeting and Record Date

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

CARDIOL THERAPEUTICS INC.

 

(Registrant)

 

 

 

Date: April 25, 2024

By:

/s/ Chris Waddick

 

 

 

 

Chris Waddick

 

Title:

Chief Financial Officer

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Cardiol Therapeutics Inc.: Exhibit 99.1 - Filed by newsfilecorp.com

April 18, 2024

Filed via SEDAR+

To All Applicable Exchanges and Securities Administrators

Subject: Cardiol Therapeutics Inc. (the "Issuer")

 Notice of Meeting and Record Date

Dear Sir/Madam:

We are pleased to confirm the following information with respect to the Issuer's upcoming meeting of securityholders:

Meeting Type: Annual General and Special Meeting
Meeting Date: June 26, 2024
Record Date for Notice of Meeting: May 13, 2024
Record Date for Voting (if applicable): May 13, 2024
Beneficial Ownership Determination Date: May 13, 2024
Class of Securities Entitled to Vote: Class A Common
ISIN: CA14161Y2006
Issuer sending proxy materials directly to NOBOs: No
Issuer paying for delivery to OBOs: Yes
Notice and Access for Beneficial Holders: Yes
Beneficial Holders Stratification Criteria: Not Applicable
Notice and Access for Registered Holders: Yes
Registered Holders Stratification Criteria: Not Applicable

In accordance with applicable securities regulations we are filing this information with you in our capacity as agent of the Issuer.

Yours truly,

 

Odyssey Trust Company

as agent for Cardiol Therapeutics Inc.

 GRAPHIC 3 exhibit99-1x1x1.jpg GRAPHIC begin 644 exhibit99-1x1x1.jpg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end